Botanee announced that its wholly-owned subsidiary, Shanghai Botanee Health Technology, has obtained a Medical Device Registration Certificate from the National Medical Products Administration for its injectable sodium hyaluronate solution. The registration number is 20263131919, effective September 10, 2026, and valid until September 9, 2031. The product is intended for superficial dermal injection in the mid-face in medical institutions to temporarily improve dry skin and dull complexion in adults. In the first half of 2026, Botanee achieved revenue of 2.592 billion yuan and net profit attributable to the parent of 292 million yuan.
Yunnan Botanee Bio-Technology Group Co LtdWholly-owned subsidiary obtained NMPA Medical Device Registration Certificate for its injectable sodium hyaluronate solution, enabling the new product to be marketed.
